Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085371 · ClinicalTrials.gov registry record · Phase 2
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
A Phase 2 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT00085371 is a Phase 2 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 116 participants, above the 72-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (61% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00085371, a Phase 2 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well triapine works as first-line or second-line therapy in treating patients with locally advanced or metastatic adenocarcinoma (cancer) of the pancreas. Drugs used in chemotherapy, such as triapine, work in different ways to stop tumor cells from dividing so they stop growing or die.
Conditions Studied
Interventions
- DRUG triapine
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2004-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085371
The ClinicalTrials.gov registry entry for NCT00085371 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 72-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (61% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Stage IV Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which triapine is the first listed.
NCT00085371 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00085371 about?
NCT00085371 is a clinical study titled "Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas". This phase II trial is studying how well triapine works as first-line or second-line therapy in treating patients with locally advanced or metastatic adenocarcinoma (cancer) of the pancreas. Drugs used in chemotherapy, such as triapine, work in different ways to stop tumor cells from dividing so the...
What is the current status of trial NCT00085371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2004-07.
What conditions does trial NCT00085371 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Recurrent Pancreatic Cancer, Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas.
What interventions are being tested in trial NCT00085371?
The interventions under investigation include: triapine (DRUG).
Who is sponsoring clinical trial NCT00085371?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00085371 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
COMPLETED · Phase 2
-
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.